Advertisment

Understanding the Impact of HER2 Status on Breast Cancer Outcomes: Current Research and Future Perspectives

author-image
Mason Walker
New Update
NULL

Understanding the Impact of HER2 Status on Breast Cancer Outcomes: Current Research and Future Perspectives

Advertisment

Role of HER2 Status in Breast Cancer

Advertisment

A recent research study by Zhu et al., analyzed 2489 breast cancer patients undergoing neoadjuvant therapy between the years 2009 and 2020. They found that HER2-low status was observed in 41.1% of the patients. Interestingly, the patients with HER2-low status exhibited higher estrogen receptor positivity compared to HER2-0 patients. This highlights the significance of the HER2 status in breast cancer, particularly in patients undergoing neoadjuvant therapy.

Pathological Complete Response and Prognostic Significance

The research also investigated the pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment. The findings showed that the pathological complete response rates were similar for HER2-low and HER2-0 patients. However, the concordance rates of HER2 and other biomarkers showed low concordance rates, suggesting a need for re-testing HER2 status post-neoadjuvant therapy in the era of anti-HER2 antibody-drug conjugates.

Advertisment

Homologous Recombination Repair Defect Status

A retrospective cohort study focused on the association between Homologous Recombination Repair Defect Status (HRD) and the long-term prognosis of early HER2 low breast cancer. The study revealed that patients with HER2 low breast cancer and homologous recombination-related gene defects had higher HRD scores. These patients were at a higher risk of acquiring certain gene mutations. The study also found variations in the association between HRD and prognosis based on hormone receptor positivity. This emphasizes the potential of HRD score as a novel biomarker to predict outcomes in patients with HER2 low EBC, and highlights the need for personalized treatments to enhance long-term outcomes.

Development of Multiplex ddPCR Assay

Advertisment

Another significant advancement in the field is the development of a single reaction multiplex ddPCR assay for the determination of ERBB2 CN in reference to two control regions. The study found that the ultrahigh ERBB2 ddPCR CN group had significantly worse survival within patients treated with adjuvant trastuzumab for both recurrence-free survival and overall survival. This suggests that accurate ERBB2 CN estimation is crucial for predicting long-term survival after trastuzumab treatment.

Next-Generation HER2-Targeted ADCs

Next-generation HER2-targeted antibody-drug conjugates (ADCs) such as trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) have been the focus of recent research. Despite the development of resistance to these drugs, there is an ongoing interest in developing better-tolerated and more effective therapeutics for breast cancer. The current state of HER2-targeted ADCs and investigational agents on the horizon provides hope for the future of breast cancer treatment.

Conclusion

In conclusion, the role of HER2 status in breast cancer prognosis is an area of intensive research. The importance of HER2 status, the need for accurate ERBB2 CN estimation, the potential of HRD score as a biomarker, and the developments in HER2-targeted ADCs are all contributing to the evolving landscape of breast cancer treatment. However, the appropriate use of statistical tools in such studies is paramount to ensure accurate conclusions and to drive the development of personalized treatments.

Advertisment
Chat with Dr. Medriva !